
Histoglob is a sterile preparation of Histamine dihydrochloride coupled to an active protein fraction extracted from human blood (Gamma-globulin) in strictly defined proportions. This conjugate is capable of eliciting an immunological response in the human body with the production of highly potent antihistaminic antibodies. Gamma-globulin used in testing. Histoglob is tested negative for HBsAg and Anti-HIV-1, 2 and Anti HCV Antibodies by ELISA and HBV, HIV & HCV by Nucleic acid is subjected to rigid stability test and electrophoretic analysis to ensure purity and safety.
Conventional antihistamines may suppress symptoms temporarily, but recurrence is common after discontinuation. In real-world study, Histoglob PFS reduced steroid use by 67% and antihistamine dependency by 53%. Consider Histoglob PFS – Trusted adjuvant immunotherapy for long-term symptom control in your patients.
In a head-to-head clinical study, Histaglobulin provided superior symptom relief compared to nasal steroids; significantly reducing rhinorrhea, congestion, and sneezing. It also lowered eosinophil counts and serum IgE levels, targeting the immunologic root of allergic rhinitis. Consider Histoglob PFS – Trusted adjuvant immunotherapy for long-term symptom control in your patients.
20–30% of Indians battle allergic rhinitis, and around 35 million struggle with asthma. Conditions where standard treatments often fall short. Choose Histoglob for targeted, long-term immune support.
Up to 20% of individuals may experience urticaria in their lifetime, with chronic urticaria and atopic dermatitis affecting 0.5% to 5%. For long-term relief in these immune-driven conditions, consider Histoglob Adjuvant Immunotherapy.
With up to 30% of Indians suffering from allergies and over half seeking care for respiratory problems, the burden is undeniable. Histaglobulin empowers clinicians to break the allergy cycle and improve patient outcomes.
Disclaimer:
The views and opinions expressed in this testimonial/video are of the healthcare providers and
are based on their experiences and do not necessarily reflect the views of BSV and/or its
officials. BSV hereby disclaims any and all liability arising directly or indirectly from any
use of the media content.
For adverse events please email us at pv@bsvgroup.com or connect with us via AER Form